Table 2

Prevalence of diabetes mellitus (DM) with and without cardiometabolic comorbidities by sex, Cameron County Hispanic Cohort (CCHC) and Population Study of Urban, Rural, and Semi-Urban Regions for the Detection of Endovascular Disease (PURSE) cohorts

Metabolic characteristicCCHCPURSE
MaleFemaleMaleFemale
% DMOR* (95% CI)% DMOR (95% CI)% DMOR (95% CI)% DMOR (95% CI)
Obese†49.05.1 (1.3 to 20.9)25.61.7 (0.7 to 4,3)40.71.4 (1.1 to 1.7)30.91.4 (1.1 to 1.8)
Non-obese13.815.126.317.0
Hypertensive‡41.31.2 (0.3 to 4.6)34.51.7 (0.7 to 4.1)37.71.0 (0.7 to 1.4)42.21.6 (1.4 to 1.9)
Normotensive23.612.628.319.4
Hypertriglyceridemia§50.03.4 (1.3 to 8.8)28.71.8 (0.6 to 4.7)41.31.7 (1.5 to 2.0)42.21.9 (1.6 to 2.3)
Normal triglycerides11.816.026.418.8
Reduced HDL¶57.23.7 (1.1 to 12.3)24.41.1 (0.4 to 2.7)33.11.0 (0.8 to 1.1)24.70.9 (0.9 to 1.0)
Normal HDL14.316.529.823.7
Insulin resistance56.64.3 (1.0 to 19.5)49.15.1 (2.1 to 12.3)58.13.8 (3.2 to 4.7)51.85.0 (3.8 to 6.9)
No insulin resistance25.214.023.615.2
  • *OR for DM versus no DM, controlling for all other metabolic characteristics and age. Statistical significance at the 5% level is marked with boldface entries.

  • †BMI ≥ 30 kg/m2 in the CCHC; BMI ≥ 25.0 in PURSE.

  • ‡Systolic blood pressure ≥ 135 or diastolic blood pressure ≥ 85 or taking antihypertensive medication.

  • §Fasting triglyceride levels ≥ 150 mg/dL.

  • ¶Fasting HDL levels < 50 (women) or <40 (men) or taking lipid-controlling medications.

  • **Homeostasis model of insulin resistance >75% percentile.

  • % DM, per cent prevalence of DM; BMI, body mass index; HDL, high-density lipoprotein.